Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

证券代码：600420 证券简称：国药现代 公告编号：2025-040 药品名称：枸橼酸托法替布片 剂型：片剂 规格：5mg（按 C16H20N6O 计） 注册分类：化学药品 4 类 证书编号：2025S01252 上海现代制药股份有限公司 关于全资子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团容 生制药有限公司（以下简称国药容生），收到国家药品监督管理局核准签发的枸 橼酸托法替布片《药品注册证书》。现将相关情况公告如下： 一、药品基本信息 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 药品批准文号：国药准字 H20254068 上市许可持有人：国药集团容生制药有限公司 药品生产企业：国药集团容生制药有限公司 二、药品研发及市场情况 枸橼酸托法替布片是一种新型的口服蛋白酪氨酸激酶抑制剂，临床适用于类 风湿关节炎、银屑病关节炎、强直性脊柱炎等。 米内网数据库显 ...

Core Viewpoint - The announcement indicates that China National Pharmaceutical Group Modern has received approval for a new drug, tofacitinib citrate tablets, which is expected to enhance its product portfolio in the oncology and immunomodulatory sectors [1] Group 1: Drug Approval and Market Impact - The full subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has obtained the drug registration certificate for tofacitinib citrate tablets from the National Medical Products Administration [1] - Tofacitinib citrate tablets are a novel oral protein tyrosine kinase inhibitor, clinically applicable for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [1] - According to the Meini Network database, the projected sales for public medical institutions in China for 2024 is approximately RMB 477 million [1] Group 2: R&D Investment and Competitive Position - The cumulative R&D investment for the development of tofacitinib citrate tablets by China National Pharmaceutical Group Rongsheng is about RMB 15.5368 million [1] - The approval of the drug registration certificate, which is considered equivalent to passing the consistency evaluation, will enrich the company's formulation product line in the oncology and immunomodulatory fields [1] - This development is expected to enhance the company's comprehensive market competitiveness in related medication areas [1]

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

Group 1 - Shengyi Electronics plans to repurchase shares with a total amount between 50 million and 100 million yuan, at a price not exceeding 43.02 yuan per share, for employee stock ownership plans [1] - Guoyao Modern's subsidiary has passed the consistency evaluation for the quality and efficacy of a generic drug, which is used for treating severe infections [1] - Tianhe Magnetic Materials' subsidiaries have obtained project filing notices for high-performance rare earth permanent magnet projects, with total investments of 100 million yuan and 50 million yuan respectively [1][2] Group 2 - Dream Lily intends to repurchase shares with an amount between 85 million and 170 million yuan, at a price not exceeding 10.90 yuan per share, supported by a loan commitment of up to 150 million yuan [3] - Weifu High-Tech has received a loan commitment of up to 135 million yuan from a financial institution for share repurchase [3] Group 3 - Lu'an Environmental Energy reported a coal sales volume of 4.51 million tons in April, a year-on-year increase of 17.75% [5] - *ST Tianshan reported a significant decline in livestock sales and revenue, with a revenue of 70,500 yuan in April, down 95.68% year-on-year [7] Group 4 - Feirongda announced a cash dividend of 0.38 yuan per 10 shares, with a total distribution of 21.9 million yuan [8] - Zhejiang Rongtai's shareholders and executives plan to reduce their holdings by up to 1.93% of the company's shares [9] Group 5 - Changhua Group's subsidiary won the land use rights for an industrial site in Ningbo for 27.05 million yuan, intended for manufacturing and related business [11] - Zejing Pharmaceutical's new drug application for a treatment for severe alopecia has been accepted by the regulatory authority [13][14] Group 6 - Hainan Mining plans to distribute a cash dividend of 0.8 yuan per 10 shares, totaling 1.59 billion yuan [15] - China Jushi plans to distribute a cash dividend of 0.24 yuan per share, totaling 9.61 billion yuan [16] Group 7 - Zhengzhong Design's subsidiary has obtained a utility model patent for an acrylic signage guide [18] - Rundu Co., Ltd. received approval for a veterinary drug product, which is intended for treating bacterial diseases in livestock [20] Group 8 - Emei Mountain A announced the resignation of its general manager due to work reasons [22] - Tonghua Dongbao's insulin injection has received a registration certificate in Nicaragua, allowing for sales in that market [23] Group 9 - Dizu Fashion's subsidiary has completed the registration of a private equity investment fund [24] - Ningbo Gaofa plans to increase capital by 60 million yuan in its subsidiary for operational needs [26] Group 10 - Haichuan Intelligent has obtained two utility model patents for material handling devices [27] - Newland's subsidiary signed a deep cooperation agreement with Alibaba Cloud for AI model applications [29] Group 11 - Rui Neng Technology's controlling shareholder plans to reduce its stake by up to 2.89% [30] - Guomai Culture intends to repurchase shares between 50 million and 100 million yuan for capital reduction [31] Group 12 - Shaanxi Construction won major construction projects totaling 7.88 billion yuan in April [32] - Hanyu Pharmaceutical signed a joint development agreement for a new peptide drug with a partner [34] Group 13 - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a stock suspension [35] - Haizheng Pharmaceutical plans to repurchase shares between 50 million and 100 million yuan for employee stock ownership [36] Group 14 - Tianqiao Hoisting's controlling shareholder plans to increase its stake by 75 million to 150 million yuan [37] - Tiandi Online's controlling shareholder is transferring shares to introduce a strategic investor [38] Group 15 - Hongchang Technology plans to invest 15 million yuan in a joint venture with a partner [39] - Rabbit Baby's subsidiary is preparing for an IPO in Hong Kong [41] Group 16 - Wol Nuclear Materials is planning to issue H-shares for listing in Hong Kong [42] - Tangyuan Electric plans to raise up to 864 million yuan through a private placement for various projects [43] Group 17 - Tongrun Equipment's major shareholders plan to reduce their holdings by up to 2% [44] - Linzhou Heavy Machinery plans to raise up to 600 million yuan through a private placement [46] Group 18 - China Merchants Securities announced the resignation of its vice president [47] - Shangsheng Electronics plans to issue convertible bonds to raise up to 330 million yuan for various projects [48] Group 19 - Longda Co., Ltd.'s major shareholder plans to reduce its stake by up to 1% [49] - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [50] Group 20 - Silek has signed a strategic cooperation agreement with a battery manufacturer [51] - Boyun New Materials' major shareholder plans to reduce its stake by up to 3% [53]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团容 生制药有限公司（以下简称国药容生）收到国家药品监督管理局核准签发的《药 品补充申请批准通知书》，批准硫酸阿米卡星注射液通过仿制药质量和疗效一致 性评价（以下简称一致性评价）。现将相关情况公告如下： 一、药品基本信息 药品名称：硫酸阿米卡星注射液 剂型：注射剂 注册分类：化学药品 规格：2ml:0.2g（20 万单位）（按 C₂₂H₄₃N₅O₁₃计） 通知书编号：2025B02041 原药品批准文号：国药准字 H41020097 上市许可持有人：国药集团容生制药有限公司 药品生产企业：国药集团容生制药有限公司 申请事项：仿制药质量和疗效一致性评价 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医 疗器械审评审批制度的意见》（国发〔2015〕44 号）、《关于仿制药质量和疗 效一致性评价工作有关事项的公告》（2017 年第 100 号）和《国家药监局关于 开展化学药品注射剂仿制药质量和疗效一致性评价 ...

| 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300740 | 水羊股 份 | 7.34 | 11.92 | 1365.96 | 2.37 | | 002762 | *ST金 比 | 1.87 | 6.12 | 764.00 | 12.09 | | 002172 | 澳洋健 康 | -1.64 | 5.20 | 490.76 | 3.40 | | 600572 | 康恩贝 | 0.00 | 0.81 | 453.06 | 4.92 | | 002566 | 益盛药 业 | 0.56 | 2.84 | 449.27 | 9.45 | | 000516 | 国际医 学 | -2.10 | 1.02 | 173.25 | 1.49 | | 603139 | 康惠制 | -1.57 | 1.79 | -62.03 | -1.77 | | | 药 | | | | | | 000615 | *ST 美 | 0.63 | 1.59 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-038 上海现代制药股份有限公司 关于参加 2025 年上海辖区上市公司年报集体业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 投资者可于 2025 年 5 月 9 日（星期五）至 5 月 14 日（星期三）16:00 前，登录上证路演中心网站首页，点击"提问预征集"栏目或通过公司邮箱 xd_zhengquanban@sinopharm.com 进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 上海现代制药股份有限公司（以下简称公司）已于 2025 年 3 月 28 日及 2025 年 4 月 29 日分别发布了《2024 年度报告》及《2025 年第一季度报告》。为便于 广大投资者更全面深入地了解公司经营成果、财务状况，公司计划于 2025 年 5 月 15 ...

Core Viewpoint - The company, Shanghai Modern Pharmaceutical Co., Ltd., announced that its wholly-owned subsidiary, National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received approval for potassium chloride injection to pass the consistency evaluation of generic drug quality and efficacy, which is expected to enhance market expansion and sales potential for the product [6][7]. Financial Data - The quarterly financial report for the first quarter of 2025 has not been audited [3]. - The company has invested approximately RMB 1.6354 million in the research and development of potassium chloride injection [8]. Drug Information - Potassium chloride injection is a commonly used medication for supplementing potassium in the body, primarily used to treat and prevent hypokalemia, especially when oral supplementation is not possible [7]. - The sales revenue of potassium chloride injection in public medical institutions across China was RMB 619 million in 2023 [7]. Regulatory Approval - The approval was granted based on various regulations, including the Drug Administration Law of the People's Republic of China and related announcements regarding the consistency evaluation of generic drugs [6].

Financial Performance - The company reported a basic earnings per share of 0.2695 yuan for Q1 2025, representing a 9.11% increase compared to 0.2470 yuan in Q1 2024 and a significant rise from 0.1529 yuan in Q1 2023 [1] - The net profit for Q1 2025 was 3.61 billion yuan, up 9.06% from 3.31 billion yuan in Q1 2024 and a substantial increase from 1.79 billion yuan in Q1 2023 [1] - Operating revenue decreased to 26.07 billion yuan in Q1 2025, down 16.52% from 31.23 billion yuan in Q1 2024 and also lower than 34.17 billion yuan in Q1 2023 [1] - The return on equity (ROE) improved to 2.70% in Q1 2025 from 2.64% in Q1 2024 and 1.72% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 82,576.74 million shares, accounting for 61.56% of the circulating shares, which is a decrease of 2,664.93 million shares from the previous period [1] - Shanghai Pharmaceutical Industrial Research Institute Co., Ltd. remains the largest shareholder with 23,951.26 million shares, representing 17.86% of the total share capital, unchanged from the previous report [2] - China Pharmaceutical Investment Co., Ltd. and China National Pharmaceutical Group Corporation also maintained their holdings at 17,400.56 million shares (12.97%) and 15,309.16 million shares (11.41%), respectively [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares in the current period [3]